Table 5.

Time to Approval of PCSK9 Inhibitors
	n	Visit with provider to receipt of approval letter (days)
Clinical team Members		Average time (+/− SD)	Median (IQR)	Range
RN and Physician	81	56.1 (+/− 47.6)	44 (18, 78)	4–196
APP, Clinical Pharmacist and MA*	138	19.9 (+/− 23.4)	12 (7, 23.75)	0–151
APP, Clinical Pharmacist, MA and specialty pharmacy services†	26	8 (+/− 9.3)	6 (2.5, 7)	1–35
Overall	245	30.6 (+/− 37.3)	15 (7, 35)	0–196
Time to First Injection of PCSK9 Medications
		Visit with provider to first injection (days)
Clinical team Members		Average time (+/− SD)	Median (IQR)	Range
RN only	92	75.4 (+/− 54.1)	64.5 (35.75, 94.5)	14–319
APP, Clinical Pharmacist and MA*	134	45.4 (+/− 55.8)	31 (22, 49.75)	8–557
APP, Clinical Pharmacist, MA and specialty pharmacy services‡	17	22.4 (+/− 19.0)	17 (8, 29)	3–70
Overall	243	55.2 (+/− 55.8)	38 (24, 68.5)	3–557

APP = advanced practice provider; IQR = interquartile range; MA = medical assistant; RN = registered nurse; SD = standard deviation

^*P<0.001 vs RN only

^†P<0.001 vs APP, Clinical Pharmacist, MA

^‡P=0.0016 vs APP, Clinical Pharmacist, MA